P-80 Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON

Markus Peck‐Radosavljevic; Riccardo Lencioni; Kirhan Özgürdal; Masatoshi Kudo

doi:10.1016/j.annonc.2021.05.135

Related publications

Article2016

Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

Jorge A. Marrero, Masatoshi Kudo, Alan P. Venook, Sheng-Long Ye, Jean-Pierre Bronowicki, Xiao‐Ping Chen, Lucy Dagher, Junji Furuse, Jean-François H. Geschwind, Laura Ladrón de Guevara, Christos N. Papandreou, Tadatoshi Takayama, Arun J. Sanyal, Seung Kew Yoon, Keiko Nakajima, Robert Lehr, Stephanie Heldner, Riccardo Lencioni

Article2024

Applying Clinical Risk Scores in Real-World Practice

Geoffrey D. Barnes, Professor Gregory Lip

Article2016

TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON

Jean-François H. Geschwind, Masatoshi Kudo, Jorge A. Marrero, Alan P. Venook, Xiao-Ping Chen, Jean-Pierre Bronowicki, Lucy Dagher, Junji Furuse, Laura Ladrón de Guevara, Christos N. Papandreou, Arun J. Sanyal, Tadatoshi Takayama, Sheng-Long Ye, Seung Kew Yoon, Keiko Nakajima, Robert Lehr, Stephanie Heldner, Riccardo Lencioni

Article2016

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON

Masatoshi Kudo, Masafumi Ikeda, Tadatoshi Takayama, Kazushi Numata, Namiki Izumi, Junji Furuse, Takuji Okusaka, Masumi Kadoya, Satoshi Yamashita, Yuichiro Ito, Norihiro Kokudo

Article2025

Disease course of dMMR endometrial cancer in real-world clinical practice.

Michalis Liontos, Anna Svarna, Aikaterni Aravantinou Fatorou, Athanasios Michas, N Dedes, Αngeliki Andrikopoulou, Alkistis Papatheodoridi, Αριστέα-Μαρία Παπανώτα, Joanna Collaros, Eleni Zografos, Μαρία Καπαρέλου, Flora Zagouri, Meletios A Dimopoulos

P-80 Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON

Discussion(0)

Related publications

Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

Applying Clinical Risk Scores in Real-World Practice

TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON

Disease course of dMMR endometrial cancer in real-world clinical practice.